<code id='89EF1CAD86'></code><style id='89EF1CAD86'></style>
    • <acronym id='89EF1CAD86'></acronym>
      <center id='89EF1CAD86'><center id='89EF1CAD86'><tfoot id='89EF1CAD86'></tfoot></center><abbr id='89EF1CAD86'><dir id='89EF1CAD86'><tfoot id='89EF1CAD86'></tfoot><noframes id='89EF1CAD86'>

    • <optgroup id='89EF1CAD86'><strike id='89EF1CAD86'><sup id='89EF1CAD86'></sup></strike><code id='89EF1CAD86'></code></optgroup>
        1. <b id='89EF1CAD86'><label id='89EF1CAD86'><select id='89EF1CAD86'><dt id='89EF1CAD86'><span id='89EF1CAD86'></span></dt></select></label></b><u id='89EF1CAD86'></u>
          <i id='89EF1CAD86'><strike id='89EF1CAD86'><tt id='89EF1CAD86'><pre id='89EF1CAD86'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:63
          Portrait of Robert Langer. -- biotech coverage from STAT.
          Serial biotech entrepreneur Bob Langer will serve as an adviser to T.rx Capital. Pat Greenhouse/Globe Staff

          Executives from the shuttered digital health company Pear Therapeutics are launching a new VC firm, offering early access to new startups formed by serial biotech entrepreneur Bob Langer.

          Former Pear CEO Corey McCann and former licensing head Michael Langer formed the new firm, T.rx Capital, earlier this year, according to three people with knowledge of the firm and documents reviewed by STAT. Michael Langer, the son of Bob Langer, confirmed the news and that they had set a $175 million cap for its first fund.

          advertisement

          The firm will invest in therapeutics and digital health products by both forming new companies and taking pitches from early-stage startups. T.rx has brought in Everly Health executive Liz Kwo and Caris Life Sciences vice president Debbie Lin as venture partners, while current Eli Lilly business development team member Kwesi Frimpong-Boateng will be joining T.rx’s founding team. Bob Langer is a scientific adviser.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Merck, Johnson & Johnson CEOs will testify on high drug prices
          Merck, Johnson & Johnson CEOs will testify on high drug prices

          Johnson&JohnsonCEOJoaquinDuatoMICHAELBUHOLZER/AFPviaGettyImagesWASHINGTON—MerckCEORobertDavisand

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Merck CEO won’t testify in Senate, citing no expertise in drug prices

          Sen.BernieSanderstoldreportersthatMerck'sCEOrefusedtotestifyoveralackofexpertiseindrugpricing.Mariam